中国104家医院早期HER2阳性乳腺癌双靶新辅助治疗后辅助治疗现状调查报告(CSBrS-030)  

A questionnaire on the status of adjuvant therapy after dual HER2-targeted neoadjuvant therapy for patients with early-stage HER2-positive breast cancer from 104 hospitals in China(CSBrS-030)

作　　者：周思成 辛灵[1] 江泽飞 刘荫华[1] 中国临床肿瘤学会乳腺癌专业委员会 中华医学会外科学分会乳腺外科学组 ZHOU Si-cheng;XIN Ling;JIANG Ze-fei;LIU Yin-hua(Department of Thyroid and Breast Surgery,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院甲状腺乳腺外科,北京100034 [2]中国人民解放军第五医学中心肿瘤内科,北京100039 [3]不详

出　　处：《中国实用外科杂志》2024年第11期1259-1262,共4页Chinese Journal of Practical Surgery

基　　金：中国乳腺外科青年医生基金项目(No.2020-CHPASLP-01,No.CJBSRAF-2022);北京医学奖励基金会项目(No.YXJL-2020-0941-0736);北京大学第一医院青年临床研究专项课题(No.2024YC21)。

摘　　要：目的调查中国早期HER2阳性乳腺癌病人接受曲妥珠单抗+帕妥珠单抗联合细胞毒药物(简称“双靶”)方案新辅助治疗后辅助治疗现状。方法采用问卷调查方式登记了2023-01-01—2023-12-31中国104家医院经治的Ⅰ~Ⅲ期乳腺癌病例,调查内容包括收治例数、HER2阳性乳腺癌占比、HER2阳性乳腺癌接受双靶方案新辅助治疗例数、新辅助治疗病理疗效评价方法及结果、双靶新辅助治疗后辅助治疗方案选择情况。结果全国104家医院提供了75530例早期乳腺癌病人的临床病理资料。其中,7063例HER2阳性乳腺癌病人接受双靶方案新辅助治疗,4217例(59.7%)病人获得病理完全缓解(p CR),2846例未获得pCR(non-pCR)。双靶新辅助治疗后,5658例(80.1%)沿用双靶辅助治疗,360例(5.1%)仅接受曲妥珠单抗辅助治疗,1045例(14.8%)病人接受其他药物。辅助靶向治疗方案选择与ypTNM分期间差异有统计学意义(χ^(2)=1730.058,P<0.001)。结论ypTNM分期可能是HER2阳性乳腺癌双靶新辅助治疗后non-pCR病人制定后续辅助治疗方案的依据。Objective To investigate the status of adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2(HER2)positive breast cancer in China after dual HER2-targeted neoadjuvant therapy,trastuzumab plus pertuzumab,combined with cytotoxic drugs.Methods The cases of stageⅠ-Ⅲbreast cancer treated at 104 hospitals in China between January 1,2023 and December 31,2023 were inquired by a questionnaire survey.The investigation included the number of cases,the proportion of HER2-positive breast cancer,the number of cases of HER2-positive breast cancer receiving dual HER2-targeted neoadjuvant therapy,the evaluation method and results of pathological response after neoadjuvant therapy,and adjuvant therapeutic regimen after neoadjuvant therapy.Results A total of 104 hospitals participated in the questionnaire and provided clinicopathological data of 75530 patients with early-stage breast cancer,and 7063 patients(40.4%)with HER2-positive breast cancer received neoadjuvant therapy with a dual HER2-targeted regimen.4217 patients(59.7%)achieved pathologic complete response(pCR).The other 2846 patients did not achieved pCR(non-pCR).After dual HER2-targeted neoadjuvant therapy,5658 patients(80.1%)continued dual HER2-targeted adjuvant therapy,360 patients(5.1%)received trastuzumab adjuvant therapy,and 1045 patients(14.8%)received other drugs.There was significant difference between adjuvant targeted therapy in different ypTNM group(χ^(2)=1730.058,P<0.001).Conclusion ypTNM stage can provide a basis for formulating follow-up adjuvant therapy regimen for HER2-positive breast cancer patients with non-pCR after dual HER2-targeted neoadjuvant therapy.

关 键 词：乳腺癌 人类表皮生长因子受体2阳性 新辅助治疗 双靶治疗 辅助治疗 

分 类 号：R6[医药卫生—外科学]